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Abstract. Elevated serum cholesterol concentrations in mid-life increase risk for Alzheimer’s disease (AD) in later life. However,
lower concentrations of cholesterol-carrying high density lipoprotein (HDL) and its principal apolipoprotein A1 (ApoA1)
correlate with increased risk for AD. As HDL transports oxocarotenoids, which are scavengers of peroxynitrite, we have
investigated the hypothesis that lower HDL and oxocarotenoid concentrations during AD may render HDL susceptible to
nitration and oxidation and in turn reduce the efficiency of reverse cholesterol transport (RCT) from lipid-laden cells. Fasting
blood samples were obtained from subjects with 1) AD without cardiovascular comorbidities and risk factors (AD); 2) AD with
cardiovascular comorbidities and risk factors (AD Plus); 3) normal cognitive function; for carotenoid determination by HPLC,
analysis of HDL nitration and oxidation by ELISA, and 3H-cholesterol export to isolated HDL. HDL concentration in the plasma
from AD Plus patients was significantly lower compared to AD or control subject HDL levels. Similarly, lutein, lycopene, and
zeaxanthin concentrations were significantly lower in AD Plus patients compared to those in control subjects or AD patients, and
oxocarotenoid concentrations correlated with Mini-Mental State Examination scores. At equivalent concentrations of ApoA1,
HDL isolated from all subjects irrespective of diagnosis was equally effective at mediating RCT. HDL concentration is lower
in AD Plus patients’ plasma and thus capacity for RCT is compromised. In contrast, HDL from patients with AD-only was
not different in concentration, modifications, or function from HDL of healthy age-matched donors. The relative importance
of elevating HDL alone compared with elevating carotenoids alone or elevating both to reduce risk for dementia should be
investigated in patients with early signs of dementia.
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INTRODUCTION
Aging is the major risk factor for dementia. Preva-
lence rates across the world are estimated to lie between
5.9–9.4% for people aged over 65 with a third of the
>85 year old population affected. Correspondingly,
absolute incidence of age-related pathologies partic-
ularly Alzheimer’s disease (AD) is increasing [1].
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AD represents at least 70% of dementia cases and is
characterized by progressive neurodegenerative alter-
ations, gradually reducing cognitive performance with
loss of memory, orientation, and judgment. Loss of
synapses and cholinergic neurons, accumulation of
extracellular amyloid- (A) plaques, and intraneu-
ronal neurofibrillary tangles of hyperphosphorylated
tau are major hallmarks of AD brain and are implicated
in its pathogenesis. There is accumulating evidence
that vascular pathology plays a central role in dementia
onset and development, and some important infor-
mation from recent reanalyses include data from a
75+ year-old community cohort in which 49% of the
AD cases clinically diagnosed on the basis of the
NINCDS-ADRDA criteria showed a possible vascu-
lar component [2]. The next most prevalent dementia,
vascular dementia (VaD), is characterized by macroan-
giopathy and is often present as a post-stroke dementia
with overlapping traditional hallmarks of AD includ-
ing A accumulation. This and other information is
certainly very important to the clarification of vascular-
targeted preventive strategies.
Despite the increasing attention on vascular causes
of AD, its etiology remains unclear; neither genes nor
environment alone are sufficient to explain the onset of
AD in the majority of the population. Cumulative and
combined exposures to different risk factors appear to
modify dementia risk [3]. The APOE 4 allele is a well-
established risk factor for late-onset and early-onset
forms butAPOE4 is neither a prerequisite for, nor suf-
ficient to cause, AD [4]. Several other polymorphisms
have been identified from genome-wide association
studies that associate AD with lipid metabolism includ-
ing ABCA1, hepatic lipase, and ABCA7 [5, 6]. A
number of comorbidities have also been associated
with increased risk of developing dementia and share
a common dyslipidemic and metabolic phenotype
including hypercholesterolemia and type 2 diabetes
[7]. Evidence from cross-sectional and observational
studies supports an association between elevated serum
cholesterol in mid-life and later development of AD
[8]. We have shown previously that low density
lipoprotein (LDL) oxidation in AD patients with car-
diovascular comorbidities and risk factors correlates
with the degree of cognitive impairment [9]. However,
statins have not ameliorated AD in trials and there
is insufficient understanding presently to recommend
statin interventions to reduce disease risk [10].
Nevertheless, cholesterol transport and metabolism
in the brain appears to be important for the develop-
ment of AD; the centrally oxidized cholesterol product,
24s-hydroxycholesterol, is an effective inhibitor of
A formation [11]. Despite distinctive compartmen-
talization of cholesterol metabolism between the brain
and the periphery, oxidized lipids may cross-over
the blood-brain barrier. Systemically oxidized choles-
terol, 27-hydroxycholesterol, can be transported from
the periphery across the blood-brain barrier and is
increased in the AD brain [12]. Indeed, an increased
ratio of 27 : 24s-hydroxycholesterol has been proposed
to favor the formation of A [13].
Studies on the structure of the major variant apopro-
tein of LDL ApoE-4 which associates with AD
suggest that it may promote A deposition, decreases
plaque clearance, has low antioxidant-like activity, and
effects cholinergic dysfunction in AD [14]. Moreover,
an increase in membrane cholesterol, especially in lipid
rafts, may upregulate the -secretase pathway, lead-
ing to the accumulation of A40 and A42 and the
increased formation of extracellular amyloid deposits
[15]. In contrast, the concentration of plasma high-
density lipoproteins (HDL) is inversely related to the
risk of cardiovascular disease and dementia [16]. The
atheroprotective effect of HDL is largely attributed
to its key role in reverse cholesterol transport (RCT)
where excess cholesterol is exported from peripheral
cells via ABCA1 and is subsequently transported back
to the liver for excretion [17]. Recent studies have sug-
gested that RCT by HDL from AD patients is impaired
and ABCA1-mediated RCT has been shown to act as an
important A clearance mechanism in ApoE-4 mice,
where ABCA1 deficiency in mice promotes amyloid
deposition [18]. ApoA1 is the major apoprotein associ-
ated with HDL and it is prone to nitration, chlorination,
and oxidation by myeloperoxidase [19, 20]. Homocys-
teine (HCy) is frequently elevated in dementia and we
have shown previously that it is a powerful inducer
of LDL apoprotein oxidation [9, 21]. Chlorination of
tyrosine 192 and oxidation of the single methionine
residue at position 158 in ApoA1 have been associated
with impaired RCT [22, 23]. The aforementioned evi-
dence suggests that modification to ApoA1 on HDL
may contribute to impaired RCT in AD.
Healthy diets in general and the Mediterranean regi-
men in particular reduce the risk for and mortality from
AD [24]. Several studies have shown that carotenoids
reduce A accumulation and tau hyperphosphoryla-
tion and microglial and astrocyte activation in animal
models [25]. In addition, patients with moderate to
severe dementia have lower plasma levels of two major
carotenoids, lutein and lycopene, compared to patients
with mild AD or controls, and among AD patients a
lower Mini-Mental State Examination (MMSE) score
was associated with lower lutein and lycopene levels
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[26, 27]. Carotenoids are lipophilic and are transported
by lipoproteins, and the oxo-carotenoids are mainly
associated with HDL [28]. They are potent scavengers
of peroxynitrite and singlet oxygen, therefore their
depletion in dementia may promote post-translational
modifications to circulating proteins such as ApoA1
on HDL and impair RCT. We have shown previously
that a decrease of circulating carotenoids and toco-
pherols after correction for fruit and vegetable intake is
associated with increased protein oxidation in patients
with dementia [29]. Therefore we have investigated
the hypothesis that oxocarotenoid depletion in demen-
tia may render HDL more susceptible to nitration and
modified HDL may reduce the efficiency of RCT from
lipid-laden cells.
MATERIALS AND METHODS
Subject recruitment
Seventy seven community dwelling subjects were
recruited from the Neurology Outpatient Clinic Neu-
roMed in Cologne, Germany. Patients were recruited
after diagnosis with AD using NINCDS-ADRDA cri-
teria either in the presence of vascular comorbidities
and risk factors (elevated intima-media thickness of the
common carotid artery and/or type 2 diabetes mellitus)
(AD Plus group) or without cardiovascular comorbidi-
ties and risk factors (AD group) [9]. Control subjects
showed no evidence of cognitive impairment and had
no vascular comorbidities and risk factors. Informed
consent was obtained from the patients or their care-
givers according to severity of disease. Smokers as
well as subjects taking medications and/or antioxi-
dant/vitamin/iron supplements were excluded from the
study. Patients with secondary dementias or with ongo-
ing acute diseases were also excluded. The patient
demographics are reported in Table 1.
Subjects underwent full physical/neurological
examination as well as collection of medical history to
assess clinical conditions and of nutritional status by
means of a qualitative food-frequency questionnaire
modified to assess daily intake of fruits and vegetables
[27]. An ECG, two consecutive measurements of
blood pressure, a carotid duplex sonography as well
as the MMSE were performed in all subjects.
Blood sampling and measurements
This investigation conforms to the principles out-
lined in the Declaration of Helsinki and according to
local ethical committee approval. After informed con-
sent, fasting blood was collected from the antecubital
vein into EDTA tubes and kept on ice until centrifu-
gation within 2 h of collection. Plasma was frozen at
−80◦C until analysis. Plasma samples were coded and
analysis was carried out in a blind fashion.
HDL isolation and quantitation
Cholesterol concentrations were measured enzy-
matically with CHOD-PAP kits from Randox, Ireland.
Each assay included appropriate standards and cal-
ibrators. HDL was separated from the plasma by
precipitation with dextran sulphate and magnesium
chloride.
For RCT studies, HDL fractions were separated
from plasma by density gradient gel electrophore-
sis according to the method of Chung et al. [30]
and purity confirmed by agarose gel electrophoresis.
Patient and control HDL nitration was determined by
ELISA according to Weber et al. [31].
Plasma carotenoid analysis
Lycopene, -carotene, -carotene, lutein, zeaxan-
thin, and cryptoxanthin were determined by HPLC
according to Stahl et al. [32].
Table 1
Demographic profile of dementia patients and controls
Group (n) Control (n = 33) AD (n = 27) AD Plus (n = 16)
Average age (mean + SD) 73.2 ± 8.3 80.5 ± 5.7 79.4 ± 4.7
Gender (%male) 33.3 37 43.7
MMSE score (mean + SD) 29.0 ± 4.7 17.1 ± 8.0 19.5 ± 4.9
ApoE 2/2 0% 0% <1%
ApoE 2/3 21% 15% <1%
ApoE 3/3 70% 50% 56%
ApoE 3/4 10% 23% 19%
ApoE 4/4 0% 12% 12%
% with hypertension 24% 29% 58%
Body mass index Kg/m2 24.1 + 1.5 23.8 + 2 25.5 + 1.4
LDL cholesterol (mg/dL) 140.9 + 53.1 129.5 + 40.6 119 + 41.4
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In vitro HDL nitration and analysis
HDL (200g/ml) was incubated with the NO donor,
spermine NONOate (30M) in the presence or absence
of homocysteine at 37◦C in the absence or presence of
10M copper for 16 h. Oxidative reactions were ter-
minated by the addition of DPTA. Five micrograms of
HDL was lyophilized to dryness, and dissolved in 20l
of 8 M urea/25 mM ammonium bicarbonate, pH 8.0,
diluted further to lower urea concentration and digested
with trypsin (1 : 50 protease to protein ratio) at 37◦C
for 4 h. The tryptic peptide pool was lyophilized to
dryness, dissolved in 0.5% acetic acid, and analyzed
by RP-HPLC-MS/MS on a Surveyor HPLC system
and a 0.075 × 100 mm C18 RP column (Proxeon), at
≈1.5l/min, connected online via nano-electrospray
with a LXQ linear ion trap mass spectrometer (Ther-
moFisher). Solvents were 99.5% water and 0.5% acetic
acid (buffer A) and 90% acetonitrile, 9.5% water, and
0.5% acetic acid (buffer B). Peptides were eluted over
a 90-min gradient from 5% to 60% solvent B and mon-
itored by data dependent analysis MS/MS scans for the
masses corresponding to tyrosine nitration and methio-
nine oxidation (+45, +16 respectively).
Western blot
HDL nitration and ABCA1 expression in differen-
tiated THP1 cells were assessed by western blotting.
Protein samples from NO/HCy/Cu-modified HDL
or differentiated THP-1 cells (10g) were separated
by 1D SDS-PAGE (12.5% gel) and electroblotted onto
polyvinylidene fluoride (PVDF) membrane. After elec-
troblotting at 20 mA for 16 h, membranes were blocked
in Tween 20 (1%) Tris Buffered Saline (TTBS) con-
taining 3% bovine serum albumin (BSA) for 2 h.
Membranes were incubated with either mouse mono-
clonal antibody against 3-nitrotyrosine or anti-ABCA1
(1 : 1000) overnight. The membranes were washed with
TTBS (6 × 15 min) before incubation with a peroxi-
dase conjugated secondary antibody (Sigma Aldrich,
Poole, UK) for 2 h (1 : 4000) peroxidase conjugated
anti goat IgG (diluted in TTBS containing 0.3% BSA).
Membranes were rinsed in TBS (6 × 15 min) and then
a chemiluminescent substrate (ECL Plus, Little Chal-
font, Amersham Biosciences) was used to visualize
detected proteins. The images recorded using a GS 710
calibrated imaging densitometer. Bands were analyzed
and quantified using Scion software (NIH, USA).
Carbonyl and 3-nitrotyrosine ELISAs
To determine protein oxidation and nitration in
plasma proteins and in HDL isolated by density gra-
dient centrifugation, proteins were diluted to 10g
/ml carbonate buffer prior to analysis by ELISA as
previously described [31, 33].
Differentiation protocol
Human THP-1 monocyte cells were seeded into
six-well plate at 1.8 × 106 cells per well in RPMI
1640 medium + GlutaMAXTM1 containing bovine
fetal serum (10%, v/v), penicillin (50 unit/ml), and
streptomycin (50g/ml). Cells were differentiated into
macrophages in the presence of phorbol 12-myristate
13-acetate (PMA, 100 ng/ml) for 5 days and medium
was replaced at least every 48 h.
Reverse cholesterol transport
Macrophages were transformed into foam cells by
incubation with oxidized LDL (50g/ml) in serum free
medium containing BSA (1.5%, w/v) for 48 h includ-
ing [3H]-cholesterol (0.1Ci/ml). The medium was
then removed and the cells were washed and incubated
in serum free medium with BSA (1.5%, w/v), ApoA1
(10g/ml), or HDL (10g/ml) for 24 h to determine
efflux.
The supernatant was collected and cells were
washed, retaining the supernatant for further analysis.
The entire pellet was lysed with 1 ml 20% triton-X100
and 5 ml Optiphase ‘Hisafe’3 liquid scintillation cock-
tail was added before radioactivity determination.
RESULTS
Patients in the AD Plus group had significantly
higher body mass index (p < 0.05) than control subjects
and hypertension was twice as frequent; however, LDL
cholesterol was not different between groups (Table 1).
The APOE 4 allele was present in AD and AD Plus
patients at three times the frequency of control sub-
jects (Table 1). HDL cholesterol was lower in AD Plus
patients but not in the plasma from patients with AD
when compared with control subjects (Fig. 1A). Sim-
ilarly, analysis of plasma carotenoid levels revealed
that lutein, lycopene, and zeaxanthin concentrations
were significantly lower in the AD Plus group but
not in control subjects or AD patients (Figs. 1B-D).
However, -carotene, -carotene, and cryptoxanthin
were not significantly different between any of the
patient groups and controls (data not shown). MMSE
correlated positively with plasma HDL, lutein, and
zeaxanthin but not lycopene, -carotene, -carotene,
and cryptoxanthin. As HDL is the principal carrier of
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Fig. 1. Plasma HDL and carotenoids are depleted in AD Plus. A) HDL cholesterol concentration (mg/dl) was analyzed in plasma from patients
with AD, AD Plus, and age-matched control subjects by dextran sulfate-magnesium precipitation using Randox kit. Plasma lutein (B), lycopene
(C), and zeaxanthin (D) were determined in plasma from patients in the AD group, AD Plus group, and age-matched control subjects by HPLC.
Data are expressed as mean and 95% confidence interval and differences were evaluated by ANOVA where ∗p < 0.05; ∗∗p < 0.01; and ∗∗∗p < 0.005.
specific carotenoids including lutein and zeaxanthin,
it may be anticipated that lower plasma carotenoid
concentrations mirror the reduction in plasma HDL
concentration. However, the correlations of both zeax-
anthin and lutein with MMSE were maintained after
correcting the carotenoid concentration per mole of
HDL cholesterol.
Nitration of ApoA1 and HDL was induced
by homocysteine/nitric oxide and copper oxida-
tion (Fig. 2A). HDL carbonyl content was elevated
in the presence of homocysteine and copper,
and was attenuated by the presence of spermine
NONOate (Fig. 2B). Conversely, protein nitra-
tion was increased when HDL was co-incubated
with homocysteine, spermine NONOate, and cop-
per. By MS, three oxidized methionine containing
peptides were present ETEGLRQEM*SKDLEEVK,
KWQEEM*ELYR, LSPLGEEM*R corresponding to
methionine 86, 112 and 148; and one nitrated peptide
LAEY*HAKATEHLSTLSEK corresponding to tyrosine
nitration at position 192 was identified. RCT from
cholesterol-loaded macrophages was diminished after
modification to HDL by homocysteine, copper with
and without spermine nonoate (Fig. 2C). However, for
HDL isolated from patient and control plasma, RCT
was not significantly different whether HDL was iso-
lated from patients with and without dementia and
controls on a mol/mol basis (Fig. 3A). When choles-
terol efflux was corrected to HDL concentration found
in the plasma, RCT was significantly lower in the AD
Plus group (Fig. 3B).
There was a tendency for HDL to be nitrated to a
greater extent in the AD Plus group, however, there
was no significant difference in HDL nitration or oxi-
dation (Fig. 3C, F) nor were total plasma levels of
3-nitrotyrosine or protein carbonyl different between
any of the subject groups studied (Fig. 3D, E).
DISCUSSION
Here we have shown for the first time that plasma
HDL, lutein, and zeaxanthin concentrations are lower
in the AD Plus patient group and thus their effective
capacity in plasma to mediate RCT is lowered. MMSE
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Fig. 2. Oxidized and nitrated HDL is less effective in reverse cholesterol transport. A) HDL treated with 30M spermine NONOate (SNO),
10M copper, and 50M homocysteine (HCy) show the greatest increase in 3-nitrotyrosine level as determined by western blotting. B) HDL
carbonyl content determined by ELISA was increased significantly by HCy/Cu and this was attenuated in part by spermine NONOate. C) RCT
measured as 3H-cholesterol efflux is impaired to nitrated and oxidized HDL. Differences were evaluated by ANOVA where ∗p < 0.05; ∗∗p < 0.01.
correlated positively with plasma HDL, lutein, and
zeaxanthin suggesting that increasing HDL cholesterol
and increasing carotenoids may also improve cognitive
outcomes for patients.
HDL plays a critical role in RCT within the systemic
circulation, removing cholesterol from peripheral
tissues for hepatic degradation. Disturbances in choles-
terol metabolism are common to a number of
pathologies which increase the risk for development of
dementia in later life [34]. The present study demon-
strates that HDL function and nitration levels are not
different between patients with cognitive impairment
and age-matched control subjects, but that in patients
with AD and vascular comorbidities/risk factors the
HDL levels are significantly lower.
Previous work has shown in a longitudinal study
that lowering of HDL over five years associates with
a significant decline in memory [35]. The InChianti
study showed that among community-dwelling older
people, those with dementia had significantly lower
total cholesterol, non-HDL-cholesterol (HDL-C), and
HDL-C levels; however, using multivariate analysis
only low HDL-C was associated with dementia [16].
These results are consistent with our findings and
suggest the existence of an independent relationship
between the pathologic vascular component of AD and
low HDL-C levels.
Peripheral cholesterol metabolism is considered
to be completely separate from brain cholesterol
metabolism, however, HDL can cross the blood-
brain barrier [36]. The mechanisms by which HDL
may exert a protective effect include the assembly
with A to mediate RCT [37], RCT from tissue via
ABCA1-dependent pathways, and through delivery of
carotenoids and tocopherols [35].
Many of the recently described functions of HDL
are not strictly attributed to its capacity to promote
cholesterol flux, but by the other molecules it trans-
ports. These include proteins, small RNAs, bioactive
lipids, hormones, vitamins, and carotenoids [38, 39]. In
chickens with ABCA1 deficiency, circulating HDL and
carotenoid concentrations were low and tissue depo-
sition of lutein was reduced to 5% of control animal
tissue levels [40]. Another carotenoid, astaxanthin, has
been described as an important inducer of ABCA1
expression in macrophages and plays an important role
in movement of cholesterol to HDL [41]. A large per-
centage of the polar oxocarotenoids are found on HDL
(lutein, 53%; zeaxanthin and cryptoxanthin, 39%) but
while HDL only transports a small percentage of total
plasma non-polar carotenoids (e.g., lycopene, 17%; -
carotene, 26%; and -carotene, 22%) [38], it has been
suggested that the content of -carotene per unit lipid
is greater in HDL than in LDL hence are likely to play
an important role in protecting HDL from modifica-
tion by free radicals [28]. Lowered HDL concentration
is associated with reduced carotenoid transport which
may influence the expression of proteins involved in
RCT, e.g., ABCA1 [42].
In the present work, we show that the oxo-
carotenoids, lutein and zeaxanthin, and lycopene are
significantly depleted in the plasma of patients in the
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Fig. 3. HDL modification and function were not different between AD (n = 28), AD plus (n = 16), and controls (n = 33). A) RCT measured
as 3H-cholesterol efflux to equivalent molar HDL concentrations isolated from plasma. B) RCT measured as 3H-cholesterol efflux to HDL
in plasma isolated from patients with and without dementia and controls. C) 3-nitrotyrosine (3NT) in HDL was determined by ELISA. D)
3-nitrotyrosine levels in plasma proteins were determined by ELISA. E) Plasma protein carbonyl levels were determined by ELISA. F) HDL
carbonyl levels determined by ELISA. Differences were evaluated by ANOVA where ∗p < 0.05.
AD Plus group and that their concentrations correlate
with MMSE. This deficit remains for zeaxanthin and
lutein even when adjusted for HDL cholesterol concen-
tration. Hence either a decrease in HDL concentration
or carotenoid concentration is expected to impact RCT
independently. Carotenoids are powerful scavengers of
singlet oxygen and so can prevent protein oxidation
and nitration in vivo and in vitro [43–46]; there is a
wealth of evidence for protein oxidation and nitration
in the periphery and brain during cognitive impair-
ment [29]. ApoA1, the major apoprotein in HDL,
is susceptible to oxidation forming a bis-sulfoxide
at methionines 112 and 148. This modification ren-
ders the molecule more susceptible to denaturation,
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reduces the formation of discoid dimeric and tetrameric
aggregates which are essential for reverse cholesterol
function, and favors formation of amyloid like fibrils
[47, 48]. HDL from atherosclerotic lesions and periph-
eral blood of patients with coronary artery disease also
contain chlorinated, nitrated, and oxidized residues
most likely arising from myeloperoxidase catalyzed
oxidation. Others have shown that oxidation of Met148
to methionine sulfoxide was associated with loss of
HDL RCT activity and Tyr192 was found to be the
predominant site for nitration and chlorination when
MPO or ONOO− were used to oxidize ApoA1; tyro-
sine chlorination and methionine oxidation markedly
reduced the cholesterol efflux activity of ApoA1 [22,
23]. In the present study, we have shown that oxidation
and nitration of HDL occur in parallel in the pres-
ence of spermine NONOate, homocysteine, and copper
resulting in methionine oxidation at 86, 112, and 148,
nitration of Tyr192 and that RCT to HDL was impaired
after modification. To explore whether the depletion
of carotenoids in AD Plus patients was associated
with tyrosine nitration or protein carbonyl formation,
plasma HDL and total plasma proteins were ana-
lyzed by 3-nitrotyrosine and protein carbonyl ELISAs
respectively. There was no significant increase in nitra-
tion of HDL in plasma from any of the patient groups
with dementia when compared to control subjects. This
differentiates dementia from general vascular diseases
where HDL nitration is prevalent [19].
A recent study has shown that RCT to AD HDL
is impaired when compared to age-matched control
HDL [49]. Our present study does not confirm this
earlier observation despite the sample size of AD and
age-matched control groups being similar between the
two studies. Unlike our AD Plus group, HDL con-
centrations in the plasma of AD patients in our study
were not different from control subject serum HDL.
However, in Khalil’s study, HDL concentrations were
lower in AD patients [49]. It is probable that the pre-
vious study did not discriminate between AD with and
without vascular pathology.
In our AD Plus patients, 3-nitrotyrosine per HDL
was 50% higher than for AD or control subjects;
conversely carotenoids and HDL concentrations were
significantly lower than in control subjects. Choles-
terol export from tissue to plasma HDL and carotenoid
transport to tissue is likely to be impaired in AD Plus
based on plasma concentration alone. The importance
of HDL as transporter of small regulatory molecules
suggest that its depletion in dementia may have wider
significance than for cholesterol metabolism alone
[38].
Despite the wealth of evidence from cross-sectional
and observational studies for an association between
elevated serum cholesterol in mid-life and later devel-
opment of AD, there is insufficient understanding to
recommend statin interventions to reduce disease risk,
probably due to the significant role of individual life-
history at particular ages and the lack of investigation
in well-characterized sub-cohorts, e.g., AD Plus [10].
In some studies, statin therapy has been effective in
modifying plasma lipids levels, but not adequate as
a monotherapy to normalize the HDL subclass distri-
bution phenotype [50]. In the field of coronary heart
disease, interest is growing to elevate HDL cholesterol
rather than just reducing total cholesterol to reduce risk
of cardiovascular events [51]. The present data sug-
gest that increasing HDL cholesterol and increasing
carotenoids may also improve cognitive outcomes for
patients. This effect may be achieved through increas-
ing transport of carotenoids to tissues and promoting
export of A and cholesterol from tissues. The relative
importance of elevating HDL alone compared with ele-
vating carotenoids alone or elevating both to reduce
risk for dementia should be investigated in patients
with early signs of dementia.
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